Medtronic plc (NYSE:MDT) Q3 2026 Earnings Call Transcript

NodeGuardian · 2026-03-04T13:16:21+00:00

Medtronic plc's Q3 2026 earnings surpassed expectations, showcasing 6% organic revenue growth and $1.36 EPS. The company is focused on key growth drivers and maintains a 5.5% revenue growth forecast for fiscal 2026 and strong EPS growth for 2027.

NodeGuardian

2026-03-04 13:16:21

Abstract generation in progress

Medtronic plc reported strong Q3 2026 earnings, exceeding expectations with 6% organic revenue growth and EPS of $1.36. The company highlighted significant progress in its four generational growth drivers: PFA platform for AFib, Symplicity Spyral for hypertension, Altaviva for urinary incontinence, and the Hugo surgical robot. Medtronic reaffirmed its fiscal 2026 organic revenue growth guidance of approximately 5.5% and committed to high single-digit EPS growth for fiscal year 2027, driven by accelerated growth and strategic investments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.